

UTILITY PATENT APPLICATION TRANSMITTAL		CERTIFICATE UNDER 37 C.F.R. 1.10	Docket No. IVD 919-4
(Only for new nonprovisional application under 37 CFR 1.53(b))		Express Mail Label No.: EL676469634US	
		Date of Deposit: <u>March 22, 2004</u>	
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service on the date indicated above, and is addressed to: Commissioner for Patents, Box Patent Application, Washington, DC 20231	
		<u>Geraldine D. Ober</u> Signature	
		ADDRESS TO: Commissioner for Patents Box Patent Application Washington, DC 20231	22581 U.S. PTO 101805733
<div>1. <input checked="" type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</div> <div>2. <input checked="" type="checkbox"/> Specification Total Pages <u>172</u> (preferred arrangement set forth below)<ul style="list-style-type: none"><li>- Descriptive Title of the Invention</li><li>- Cross References to Related Applications</li><li>- Statement Regarding Fed sponsored R &amp; D</li><li>- Reference to Sequence Listing or a Table Appendix</li><li>- Background of the Invention</li><li>- Brief Summary of the Invention</li><li>- Brief Description of the Drawings (if filed)</li><li>- Detailed Description</li><li>- Claim(s)</li><li>- Abstract of the Disclosure</li></ul></div> <div>3. <input type="checkbox"/> Drawing(s) (35 USC 113) Total Sheets <input type="checkbox"/></div> <div>4. <input checked="" type="checkbox"/> Oath or Declaration/ Total Sheets <u>3</u> Power of Attorney<ul style="list-style-type: none"><li>a. <input type="checkbox"/> Newly executed (original or copy)</li><li>b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 16 completed)</li><li>i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</li></ul></div> <div>5. <input type="checkbox"/> Application Data Sheet (See 37 CFR 1.76)</div> <div>6. <input type="checkbox"/> CD-Rom or CD-R, Large Table or Computer Program (Appendix)</div> <div>7. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)<ul style="list-style-type: none"><li>a. <input type="checkbox"/> Computer Readable Form (CFR)</li><li>b. <input type="checkbox"/> Paper copy (identical to computer copy)</li><li>c. <input type="checkbox"/> Statement verifying identity of above copies</li></ul></div>			
ACCOMPANYING APPLICATION PARTS			
8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))			
9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney			
10. <input type="checkbox"/> English Translation Document (if applicable)			
11. <input checked="" type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations			
12. <input checked="" type="checkbox"/> Preliminary Amendment			
13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)			
14. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122(b)(2)(B)(i)			
15. <input checked="" type="checkbox"/> Other: <u>Citation of References</u>			
16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment or in an Application Data Sheet under 37 CFR 1.76: <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application no: <u>09/954,862</u> Prior Application Information: Examiner: <u>Charanjit Aulakh</u> Group Art Unit: <u>1625</u> For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
17. CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label <u>27546</u> or <input checked="" type="checkbox"/> Correspondence address below			
Paul E. Dupont Sanofi-Synthelabo Inc. 9 Great Valley Parkway Malvern, PA 19355 Telephone No.: (610) 889-6338 Facsimile No.: (610) 889-8799		Respectfully submitted, <u>Paul E. Dupont</u> Paul E. Dupont Reg. No. 27,438	

Application of: Bichon et al.

Docket No.: IVD 919-4

Divisional of U.S. Application Serial No. 09/954,862

FOR: Novel Human NK<sub>3</sub> Receptor-Selective Antagonist Compounds, Method  
for Obtaining Them And Pharmaceutical Compositions Containing Them

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label No.: EL676469634US

Date of Deposit: March 22, 2004

I hereby certify that this paper is being deposited with the United States  
Postal Service "Express Mail Post Office to Addressee" Service on the  
date indicated above, and is addressed to:

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

  
\_\_\_\_\_  
Signature

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional Under 37 C.F.R. 1.53(b)  
Application of: : Bichon et al.

Prior Application Serial No.: 09/954,862

Prior Filing Date: : September 18, 2001

Group Art Unit: 1625

Examiner: Aulakh, Charanjit

For: Novel Human NK<sub>3</sub> Receptor-Selective  
Antagonist Compounds, Method for Obtaining Them  
And Pharmaceutical Compositions Containing Them

Mail Stop Patent Application  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE UNDER 37 C.F.R. 1.10**

Express Mail Label Number: EL676469634US

Date of Deposit: March 22, 2004

I hereby certify that this paper is being deposited with the  
United States Postal Service "Express Mail Post Office to  
Addressee" Service on the date indicated above and is  
addressed to: Mail Stop Patent Application, Commissioner  
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Name Gurdeep Singh

**FEE TRANSMITTAL FORM**

The filing fee for the above-identified has been calculated as shown below:

	Number Filed	Claims as Filed		Rate	Basic Fee \$ 770.00
		Number	Extra		
Total Claims	23	-20 =	3	X	\$ 18.00 = \$ 54.00
Independent Claims	1	- 3 =	0	X	\$ 86.00 = \$ 0.00
Multiple dependent claims(s), if any	2				\$290.00 = \$ 290.00
Total Filing Fee:					\$1,114.00

☒ Please charge the following fees to Deposit Account No. 19-0091.


☒ Filing Fee of \$ 1,114.00  
☐ Assignment recordal fee of \$

Please charge any additional fees under 37 CFR 1.16 which may be required, or credit any overpayment, to Deposit Account No. 19-0091. A duplicate copy of this sheet is enclosed.

☒ This application is being filed by "Express Mail" as of the date of this letter pursuant to 37 CFR 1.10(b).

Date: 3/22/04

Address:  
Patent Department  
Sanofi-Synthelabo Inc.  
9 Great Valley Parkway  
Malvern, PA 19355  
Tele: (610) 889-6338  
Fax: (610) 889-8799

  
Paul E. Dupont  
Reg. No. 27,438